EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study

Ahmad Basil Nasir iD, Yassine Kilani, Mohammad Aldiabat, Omar Abdelghany, Youssef Hafez, Nitin Desai, Mahmoud Y Madi, Francis G Wade, Kamran Qureshi, Lewis J Frey, Adam D Farmer, Wing-Kin Syn iD

PLOS One · 2026

DOI: 10.1371/journal.pone.0356138 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift PLOS One, 2026. Verfasst von Ahmad Basil Nasir und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, Missouri, Unite…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Cognitive Dysfunction, Cognition Disorders. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the associations between commonly used antidiabetic regimens and incidence of mild cognitive disorder, Alzheimer disease, and vascular dementia in adults with type 2 diabetes. Design, setting, and participants This retrospective cohort study used the TriNetX US Collaborative Network of electronic health records from 2010 to 2024. Adults aged 40–69 years with type 2 diabetes and at least 1 year of follow-up were included. Propensity score matching was applied to balance covariates. Exposure Patients were classified into 5 treatment groups: metformin only (reference), metformin plus DPP-4 inhibitors, metformin plus GLP-1 receptor agonists, metformin plus SGLT-2 inhibitors, and insulin monotherapy. Exposure was defined by first recorded prescription and continued use during follow-up. Main outcomes and measures Primary outcomes were incident mild cognitive disorder, Alzheimer disease, and vascular dementia, identified using ICD-10 codes. Hazard ratios with 95% confidence intervals were estimated from Cox proportional hazards models, with landmark analyses for follow-up shorter and longer than 5 years.

Results

Among 1,528,885 adults with type 2 diabetes (mean age, 58 years; 49.2% women), GLP-1 receptor agonists plus metformin were associated with lower incidence of vascular dementia (HR, 0.46; 95% CI, 0.37–0.57), mild cognitive disorder (HR, 0.79; 95% CI, 0.66–0.95), and Alzheimer disease (HR, 0.46; 95% CI, 0.31–0.70). SGLT-2 inhibitors plus metformin reduced vascular dementia risk (HR, 0.68; 95% CI, 0.54–0.87) but not other outcomes. Insulin monotherapy was associated with higher incidence of vascular dementia (HR, 3.27; 95% CI, 3.03–3.52), mild cognitive disorder (HR, 1.71; 95% CI, 1.56–1.87), and Alzheimer disease (HR, 1.56; 95% CI, 1.32–1.84). Conclusions and Relevance GLP-1 receptor agonists and SGLT-2 inhibitors combined with metformin were associated with reduced risk of cognitive decline. Insulin monotherapy was associated with higher incidence of all three outcomes; however, this association is likely influenced by confounding by indication, unmeasured markers of diabetes severity (including diabetes duration, cardiovascular and renal disease severity, and microvascular and macrovascular complications), and shorter follow-up among insulin users, and should not be interpreted as a direct drug effect. Because standard Cox models do not account for death as a competing event, reported hazard ratios reflect cause-specific hazards and may not directly correspond to cumulative incidence, particularly for the insulin group, in which mortality and censoring were substantially higher. Antidiabetic medication choice may influence long-term cognitive outcomes and should be considered in diabetes management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsCognitive DysfunctionCognition DisordersHumansFemaleRetrospective StudiesMetforminMiddle AgedMaleAgedInsulinAdultAlzheimer DiseaseDipeptidyl-Peptidase IV InhibitorsIncidenceSodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsDementia, Vascular

Substanzen

Hypoglycemic AgentsMetforminInsulinDipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, Missouri, United States of America.
  • Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, Missouri, United States of America.
  • Department of Internal Medicine, Washington University, Saint Louis, Missouri, United States of America.
  • Department of Pathology, Saint Louis University School of Medicine, Saint Louis, Missouri, United States of America.
  • VA St. Louis Healthcare System, St. Louis, Missouri, United States of America.
  • Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Vizcaya, Spain.

ORCID-Profile: Ahmad Basil Nasir, Wing-Kin Syn

Zitieren

APA

Nasir, A. B., Kilani, Y., Aldiabat, M., Abdelghany, O., Hafez, Y., Desai, N., Madi, M. Y., Wade, F. G., Qureshi, K., Frey, L. J., Farmer, A. D., & Syn, W. K. (2026). Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study. PLOS One. https://doi.org/10.1371/journal.pone.0356138

Vancouver

Nasir AB, Kilani Y, Aldiabat M, Abdelghany O, Hafez Y, Desai N, et al. Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study. PLOS One. 2026. doi:10.1371/journal.pone.0356138

BibTeX
@article{Nasir2026,
  author = {Nasir, Ahmad Basil and Kilani, Yassine and Aldiabat, Mohammad and Abdelghany, Omar and Hafez, Youssef and Desai, Nitin and Madi, Mahmoud Y and Wade, Francis G and Qureshi, Kamran and Frey, Lewis J and Farmer, Adam D and Syn, Wing-Kin},
  title = {Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0356138}
}
Kostenlos starten →